1. Clinical and Economic Outcomes Associated With Use of Liposomal Bupivacaine Versus Standard of Care for Management of Postsurgical Pain in Pediatric Patients Undergoing Spine Surgery
- Author
-
Jessica Cirillo, Robert Tracy Ballock, John Seif, Jennifer H. Lin, and Ryan C. Goodwin
- Subjects
hospitalized child ,medicine.medical_specialty ,pediatrics ,General Indications ,lcsh:Computer applications to medicine. Medical informatics ,Rate ratio ,03 medical and health sciences ,Adolescent medicine ,0302 clinical medicine ,Patient satisfaction ,030225 pediatrics ,Anesthesiology ,medicine ,health economics ,030212 general & internal medicine ,Adverse effect ,adolescent medicine ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,opioids ,Retrospective cohort study ,Confidence interval ,anesthesiology ,costs of hospital care ,Anesthesia ,spinal fusion ,Cohort ,lcsh:R858-859.7 ,business - Abstract
**Background:** Approximately 60% of hospitalized children undergoing surgery experience at least 1 day of moderate-to-severe pain after surgery. Pain following spine surgery may affect opioid exposure, length of stay (LOS), and costs in hospitalized pediatric patients. This is a retrospective cohort analysis of pediatric patients undergoing inpatient primary spine surgery. **Objectives:** To examine the association of opioid-related and economic outcomes with postsurgical liposomal bupivacaine (LB) or non-LB analgesia in pediatric patients who received spine surgery. **Methods:** Premier Healthcare Database records (January 2015–September 2019) for patients aged 1–17 years undergoing inpatient primary spine surgery were retrospectively analyzed. Outcomes included in-hospital postsurgical opioid consumption (morphine milligram equivalents [MMEs]), opioid-related adverse events (ORAEs), LOS (days), and total hospital costs. A generalized linear model adjusting for baseline characteristics was used. **Results:** Among 10 189 pediatric patients, the LB cohort (n=373) consumed significantly fewer postsurgical opioids than the non-LB cohort (n=9816; adjusted MME ratio, 0.53 [95% confidence interval (CI), 0.45–0.61]; P
- Published
- 2021
- Full Text
- View/download PDF